Entera Bio Ltd. Research and Development Expense of Revenue

Research and Development Expense of Revenue of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development Expense of Revenue for the quarter ending June 29, 2020 was 3867.31% (a 1.2% increase compared to previous quarter)
  • Year-over-year quarterly Research and Development Expense of Revenue increased by 29.92%
  • Annual Research and Development Expense of Revenue for 2019 was 3050.42% (a 79.06% increase from previous year)
  • Annual Research and Development Expense of Revenue for 2018 was 1703.6% (a Infinity% increase from previous year)
  • Twelve month Research and Development Expense of Revenue ending June 29, 2020 was 2877.73% (a 18.19% increase compared to previous quarter)
  • Twelve month trailing Research and Development Expense of Revenue increased by Infinity% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
2877.73% 2434.89% 978.13% 0.0%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development Expense of Revenue of Entera Bio Ltd.

Most recent Research and Development Expense of Revenueof ENTX including historical data for past 10 years.

Interactive Chart of Research and Development Expense of Revenue of Entera Bio Ltd.

Entera Bio Ltd. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 3867.31% 3821.43%
2019 1926.47% 2976.67% 1909.46% 0.0% 3050.42%
2018 410.8% 0.0% 0.0% 0.0% 1703.6%
2017 0.0%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.